nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»nogr-462Research ArticleЛЕКЦИЯLECTIONАСПЕКТЫ БЕЗОПАСНОСТИ ТЕРАПИИ АНТИТРОМБОЦИТАРНЫМИ ПРЕПАРАТАМИ БОЛЬНЫХ С МЕТАБОЛИЧЕСКИМ СИНДРОМОМSAFETY ASPECTS OF ANTIPLATELETS THERAPY OF PATIENTS WITH METABOLIC SYNDROMEЕдемскаяМ. А.EdemskaiaM. A.Edemskaia.m@gmail.comСМ клиникаРоссияSM clinicRussian Federation20172007201707126134Copyright © Едемская М.А., 20172017Едемская М.А.Edemskaia M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/462

Пациенты с метаболическим синдромом находятся в группе риска по развитию тромботических осложнений различной локализации, в первую очередь это касается сердечно-сосудистой системы, в связи с чем с профилактической целью широко применяются антитромбоцитарные препараты. Другой частой проблемой являются заболевания опорно-двигательного аппарата и хроническая боль другой локализации, которые вынуждают пациентов использовать нестероидные противовоспалительные препараты, но их совместный прием значительно повышает риск развития эрозивно-язвенных повреждений и желудочно-кишечных кровотечений. С профилактической и лечебной целью хорошо себя зарекомендовали ингибиторы протонной помпы, но часть из них, в свою очередь, может ослаблять эффект антитромбоцитарных препаратов. Несмотря на множество исследований, окончательного мнения о безопасности комбинации антитромбоцитарных препаратов (тиенопиридинов) и ИПП пока не сложилось.

Patients with metabolic syndrome are in a risk group of trombotic complications of various localisation. Firstly it concerns cardiovascular system thus antiplatelet drugs are widely used in order to prevent that. Another frequent problem is locomotor system diseases and chronic pain of other localisation, which compel patients to take NSADs, but taking both antiplatelet agents and NSAID greatly increase risk of emerging the ulcers and gastrointestinal bleeding. To prevent and cure such problems the proton pomp inhibitors (PPI) have worked well, but some of them, in their turn, may reduce the effect of antiplatelet drugs. Despite many researches the final decision on safety of the combination of antiplatelet drugs (tienopiridins?) and PPI hasn’t taken yet.

метаболический синдромантитромбоцитарные препаратыНПВПИППингибиторы протонной помпыцитохром P450 CYP2C 19побочные эффектыmetabolic syndromePPIadverse eventsantiplatelet agentsNSAIDcytochrome P450 CYP2C 19ReferencesБерковская М. А., Бутрова С. А. Метаболический синдром как протромбогенное и провоспалительное состояние: влияние терапевтических мероприятий. Ожирение и метаболиз, 2009, № 4.Берковская М. А., Бутрова С. А. Метаболический синдром как протромбогенное и провоспалительное состояние: влияние терапевтических мероприятий. Ожирение и метаболиз, 2009, № 4.Нейфельд И. В., Рогожина И. Е., Скупова И. Н., Бобылева И. В. Интегральная оценка системы гемостаза при постменопаузальном метаболическом синдроме. Бюллетень медицинских интернет-конференций, 2012, № 12, т. 2.Нейфельд И. В., Рогожина И. Е., Скупова И. Н., Бобылева И. В. Интегральная оценка системы гемостаза при постменопаузальном метаболическом синдроме. Бюллетень медицинских интернет-конференций, 2012, № 12, т. 2.Сумеркина В. А., Чулков Вл.С., Чулков В. С. Состояние системы гемостаза у пациентов с метаболическим синдромом. Здоровье и образование в XXI веке, 2014, № 16 (4), С. 85-88.Сумеркина В. А., Чулков Вл.С., Чулков В. С. Состояние системы гемостаза у пациентов с метаболическим синдромом. Здоровье и образование в XXI веке, 2014, № 16 (4), С. 85-88.Aburto-Mejía E, Santiago-Germán D, Martínez-Marino M, et al. Hypofibrinolytic State in Subjects with Type 2 Diabetes Mellitus Aggravated by the Metabolic Syndrome before Clinical Manifestations of Atherothrombotic Disease. BioMed Research International, 2017;2017:6519704. doi:10.1155/2017/6519704.Aburto-Mejía E, Santiago-Germán D, Martínez-Marino M, et al. Hypofibrinolytic State in Subjects with Type 2 Diabetes Mellitus Aggravated by the Metabolic Syndrome before Clinical Manifestations of Atherothrombotic Disease. BioMed Research International, 2017;2017:6519704. doi:10.1155/2017/6519704.Paneni F., Cosentino F. Diabetes and Cardiovascular Disease: AGuideto Clinical Management. - Springer International Publishing Switzerland, 2015. DOI 10.1007/978-3-319-17762-5_1.Paneni F., Cosentino F. Diabetes and Cardiovascular Disease: AGuideto Clinical Management. - Springer International Publishing Switzerland, 2015. DOI 10.1007/978-3-319-17762-5_1.Perez-Campos-Mayoral L., Pérez-Campos E., Zenteno E., et al. Better detection of platelet aggregation in patients with metabolic syndrome using epinephrine and ADP. Diabetol Metab Syndr, 2014 Aug 29;6(1):93. doi: 10.1186/1758-5996-6-93.Perez-Campos-Mayoral L., Pérez-Campos E., Zenteno E., et al. Better detection of platelet aggregation in patients with metabolic syndrome using epinephrine and ADP. Diabetol Metab Syndr, 2014 Aug 29;6(1):93. doi: 10.1186/1758-5996-6-93.Рекомендации по ведению больных с метаболическим синдромом. Клинические рекомендации. М., 2013.Рекомендации по ведению больных с метаболическим синдромом. Клинические рекомендации. М., 2013.Суслина З. А., Танашян М. М., Ионова В. Г. Ишемический инсульт: кровь, сосудистая стенка, антитромботическая терапия. - М.: Медицинская книга, 2005. - С. 248.Суслина З. А., Танашян М. М., Ионова В. Г. Ишемический инсульт: кровь, сосудистая стенка, антитромботическая терапия. - М.: Медицинская книга, 2005. - С. 248.Bhatt D. L., Scheiman J., Abraham N. S. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 2008; 118: 1894-1909; J Am Coll Cardiol, 2008; 52: 1502-17.Bhatt D. L., Scheiman J., Abraham N. S. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 2008; 118: 1894-1909; J Am Coll Cardiol, 2008; 52: 1502-17.Amsterdam E. A., Wenger N. K., Brindis R. G., Casey D. E., et al. 2014 ACC/AHA guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (published online ahead of print September 23, 2014). Circulation, doi: 10.1161/CIR.0000000000000134.2014 NSTE-ACS Clinical Practice Guidelines.Amsterdam E. A., Wenger N. K., Brindis R. G., Casey D. E., et al. 2014 ACC/AHA guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (published online ahead of print September 23, 2014). Circulation, doi: 10.1161/CIR.0000000000000134.2014 NSTE-ACS Clinical Practice Guidelines.Deepak T., Giugliano R. P. Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe. Am Heart J., 2009 Nov;158(5):695-705. doi: 10.1016/j.ahj.2009.08.023.Deepak T., Giugliano R. P. Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe. Am Heart J., 2009 Nov;158(5):695-705. doi: 10.1016/j.ahj.2009.08.023.Kolh P., Windecker S., Alfonso F., Collet J. P., et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg, 2014 Oct;46(4):517-92. doi: 10.1093/ejcts/ezu366. Epub 2014 Aug 29.Kolh P., Windecker S., Alfonso F., Collet J. P., et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg, 2014 Oct;46(4):517-92. doi: 10.1093/ejcts/ezu366. Epub 2014 Aug 29.Rydén L, Grant P. J., Anker S. D., Berne C., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J, 2013 Oct;34(39):3035-87. doi: 10.1093/eurheartj/eht108. Epub 2013 Aug 30.Rydén L, Grant P. J., Anker S. D., Berne C., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J, 2013 Oct;34(39):3035-87. doi: 10.1093/eurheartj/eht108. Epub 2013 Aug 30.Cox ER, Frisse M, Behm A, Fairman KA. Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med, 2004, 164: 1243-1246. 10.1001/archinte.164.11.1243.Cox ER, Frisse M, Behm A, Fairman KA. Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med, 2004, 164: 1243-1246. 10.1001/archinte.164.11.1243.Цурко В. В., Шавловская О. А., Фокина Н. М. НПВП - что изменилось за последние 10 лет? РМЖ, 2014, № 27, с. 1980.Цурко В. В., Шавловская О. А., Фокина Н. М. НПВП - что изменилось за последние 10 лет? РМЖ, 2014, № 27, с. 1980.Weil J., Colin-Jones D., Langman M. et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ, 1995; 310: 827-830.Weil J., Colin-Jones D., Langman M. et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ, 1995; 310: 827-830.Yeomans N. D., Lanas A. I., Talley N. J. et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther, 2005; 22: 795-801.Yeomans N. D., Lanas A. I., Talley N. J. et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther, 2005; 22: 795-801.Hansen M. L., Sørensen R., Clausen M. T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med, 2010; 170: 1433-1441.Hansen M. L., Sørensen R., Clausen M. T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med, 2010; 170: 1433-1441.Lanas A., García-Rodríguez L.A., Arroyo M. T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut, 2006; 55: 1731-1738.Lanas A., García-Rodríguez L.A., Arroyo M. T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut, 2006; 55: 1731-1738.Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ, 2006;333:726. doi: 10.1136/bmj.38947.697558.AE.Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ, 2006;333:726. doi: 10.1136/bmj.38947.697558.AE.Каминный А. И. Терапия антиагрегантами и нестероидными противовоспалительными пре- паратами. Соотношение риска и пользы. Лечащий врач, 2008, № 7, С. 1-6.Каминный А. И. Терапия антиагрегантами и нестероидными противовоспалительными пре- паратами. Соотношение риска и пользы. Лечащий врач, 2008, № 7, С. 1-6.Поражения органов пищеварения, индуцированные приемом нестероидных противовоспалительных препаратов. Под ред. А. В. Шаброва, Ю. П. Успенского. - СПб: ИнформМед, 2013.Поражения органов пищеварения, индуцированные приемом нестероидных противовоспалительных препаратов. Под ред. А. В. Шаброва, Ю. П. Успенского. - СПб: ИнформМед, 2013.Зеленская Е. М., Слепухина А. А., Кох Н. В., Апарцин К. А., Лифшиц Г. И. Генетические, патофизиологические и клинические аспекты антиагрегантной терапии (обзор литературы). Фармакогенетика и фармакогеномика, 2015, № 1, с. 12-19.Зеленская Е. М., Слепухина А. А., Кох Н. В., Апарцин К. А., Лифшиц Г. И. Генетические, патофизиологические и клинические аспекты антиагрегантной терапии (обзор литературы). Фармакогенетика и фармакогеномика, 2015, № 1, с. 12-19.Serebruany V. L., Steinhubl S. R., Berger P. B. et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol, 2005; 95: 1218-1222.Serebruany V. L., Steinhubl S. R., Berger P. B. et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol, 2005; 95: 1218-1222.Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002; 324: 71-86.Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002; 324: 71-86.Peters R. J., Mehta S. R., Fox K. A. et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation, 2003; 108: 1682-1687.Peters R. J., Mehta S. R., Fox K. A. et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation, 2003; 108: 1682-1687.Ivert T., Dalén M., Ander C., Stålesen R., et al. Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid. Thromb Res, 2017 Jan;149:64-69. doi: 10.1016/j.thromres.2016.11.018. Epub 2016 Nov 21.Ivert T., Dalén M., Ander C., Stålesen R., et al. Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid. Thromb Res, 2017 Jan;149:64-69. doi: 10.1016/j.thromres.2016.11.018. Epub 2016 Nov 21.De Abajo F. J., Garcia Rodriguez L. A. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol, 2001; 1: 1.De Abajo F. J., Garcia Rodriguez L. A. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol, 2001; 1: 1.Garcia Rodriguez L. A., Hernandez-Diaz S., de Abajo F. J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol, 2001; 52: 563-571.Garcia Rodriguez L. A., Hernandez-Diaz S., de Abajo F. J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol, 2001; 52: 563-571.Kelly J. P., Kaufman D. W., Jurgelon J. M. et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet, 1996; 348: 1413-1416.Kelly J. P., Kaufman D. W., Jurgelon J. M. et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet, 1996; 348: 1413-1416.Korte W., Cattaneo M., Chassot P.-G. et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease. GTH, ASARI and ESC. Thromb. Haemost, 2011. Vol. 105, № 5. P. 743-749.Korte W., Cattaneo M., Chassot P.-G. et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease. GTH, ASARI and ESC. Thromb. Haemost, 2011. Vol. 105, № 5. P. 743-749.Johnson D. A. Upper GI risks of NSAIDs and antiplatelet agents: key issues for the cardiologist. Rev Cardiovasc Med, 2005; 6, Suppl 4: S 15-22.Johnson D. A. Upper GI risks of NSAIDs and antiplatelet agents: key issues for the cardiologist. Rev Cardiovasc Med, 2005; 6, Suppl 4: S 15-22.Abraham N. S., Castillo D. L., Hartman C. National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use. Aliment Pharmacol Ther, 2008; 28: 97-106.Abraham N. S., Castillo D. L., Hartman C. National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use. Aliment Pharmacol Ther, 2008; 28: 97-106.Каратеев А. Е., Насонов Е. Л., Яхно Н. Н., Ивашкин В. Т., и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология, 2015; 9(1):4-23. DOI:10.14412/1996-7012-2015-1-4-23.Каратеев А. Е., Насонов Е. Л., Яхно Н. Н., Ивашкин В. Т., и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология, 2015; 9(1):4-23. DOI:10.14412/1996-7012-2015-1-4-23.http://antitromb.ru/?news=кангрелор-не-будет-в-ближайшее-время-п- сообщение об отсутствии кангрелора на российском рынке в ближайшем будущем.http://antitromb.ru/?news=кангрелор-не-будет-в-ближайшее-время-п- сообщение об отсутствии кангрелора на российском рынке в ближайшем будущем.Официальная инструкция к препарату «Плавикс» на территории РФ.Официальная инструкция к препарату «Плавикс» на территории РФ.Cresci S., Depta J. P., Lenzini P. A., Li A. Y., et al. Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel Treated Patients Following Acute Myocardial Infarction. Circulation: Cardiovascular Genetics, 2014; DOI: 10.1161/CIRCGENETICS.113.000303.Cresci S., Depta J. P., Lenzini P. A., Li A. Y., et al. Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel Treated Patients Following Acute Myocardial Infarction. Circulation: Cardiovascular Genetics, 2014; DOI: 10.1161/CIRCGENETICS.113.000303.Kazui М., Nishiya Y, Ishizuka T. et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug. Metab. Dispos, 2010, Vol. 38, p. 92-99.Kazui М., Nishiya Y, Ishizuka T. et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug. Metab. Dispos, 2010, Vol. 38, p. 92-99.Ma TKW, Lam YY, Tan VP, Yan BP. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol, 2011;72(4):697-706.Ma TKW, Lam YY, Tan VP, Yan BP. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol, 2011;72(4):697-706.Diener H.-C., Bogousslavsky J., Brass L. M., et al. On behalf of the MATCH Investigators. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): Study design and baseline data. Cerebrovasc. Dis, 2004; 77: 253-261.Diener H.-C., Bogousslavsky J., Brass L. M., et al. On behalf of the MATCH Investigators. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): Study design and baseline data. Cerebrovasc. Dis, 2004; 77: 253-261.Kolh P., Windecker S., Alfonso F., Collet J. P., et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg, 2014 Oct;46(4):517-92. doi: 10.1093/ejcts/ezu366. Epub 2014 Aug 29.Kolh P., Windecker S., Alfonso F., Collet J. P., et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg, 2014 Oct;46(4):517-92. doi: 10.1093/ejcts/ezu366. Epub 2014 Aug 29.Bhatt D. L., Fox K. A.A., Hacke W. et al. For the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 2006; 354: 1706-1717.Bhatt D. L., Fox K. A.A., Hacke W. et al. For the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 2006; 354: 1706-1717.Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001, Vol. 345, p. 494-502.Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001, Vol. 345, p. 494-502.COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45?852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 2005. Vol. 366. P. 1607-1612.COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45?852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 2005. Vol. 366. P. 1607-1612.The ACTIVE Investigators (2009) Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med 360: 2066-78.The ACTIVE Investigators (2009) Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med 360: 2066-78.Yusuf S., Zhao F., Mehta S. R., Chrolavicius S., Tognoni G., Fox K. K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med, 2001. Vol. 345. P. 494-502.Yusuf S., Zhao F., Mehta S. R., Chrolavicius S., Tognoni G., Fox K. K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med, 2001. Vol. 345. P. 494-502.Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology, 2014;147:784-92. doi: 10.1053/j.gastro.2014.06.007.Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology, 2014;147:784-92. doi: 10.1053/j.gastro.2014.06.007.Ивашкин В. Т., Шептулин А. А., Маев И. В., Баранская Е. К., Трухманов А. С., Лапина Т. Л. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению эрозивно-язвенных поражений желудка и двенадцатиперстной кишки, вызванных нестероидными противовоспалительными препаратами. РЖГГК, 2014;19(6):89-94.Ивашкин В. Т., Шептулин А. А., Маев И. В., Баранская Е. К., Трухманов А. С., Лапина Т. Л. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению эрозивно-язвенных поражений желудка и двенадцатиперстной кишки, вызванных нестероидными противовоспалительными препаратами. РЖГГК, 2014;19(6):89-94.Российские рекомендации. ВНОК. Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST электрокардиограммы. Кардиоваскулярная терапия и профилактика, 2007; тр.: 415-500.Российские рекомендации. ВНОК. Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST электрокардиограммы. Кардиоваскулярная терапия и профилактика, 2007; тр.: 415-500.O’Gara P.T., Kushner F. G., Ascheim D. D., Casey D. E., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2013 Jan 29;127(4):529-55. doi: 10.1161/CIR.0b013e3182742c84. Epub 2012 Dec 17.O’Gara P.T., Kushner F. G., Ascheim D. D., Casey D. E., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2013 Jan 29;127(4):529-55. doi: 10.1161/CIR.0b013e3182742c84. Epub 2012 Dec 17.Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика, 2011; 10 (6), прил. 2.Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика, 2011; 10 (6), прил. 2.Chan F. K., Ching J. Y., Hung L. C. et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med, 2005; 352: 238-244.Chan F. K., Ching J. Y., Hung L. C. et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med, 2005; 352: 238-244.Kim JH, Park SH, Cho CS, et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory druginduced mucosal toxicity. Gut Liver, 2014 Jul;8(4):371-9. doi: 10.5009/gnl.2014.8.4.371. Epub 2013 Dec 24.Kim JH, Park SH, Cho CS, et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory druginduced mucosal toxicity. Gut Liver, 2014 Jul;8(4):371-9. doi: 10.5009/gnl.2014.8.4.371. Epub 2013 Dec 24.Oh Yuong Lee, Dae-Hwan Kang, Dong Ho Lee, et al. A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment. Arch. Pharm. Res, 2014, vol. 37, p. 1308-1316.Oh Yuong Lee, Dae-Hwan Kang, Dong Ho Lee, et al. A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment. Arch. Pharm. Res, 2014, vol. 37, p. 1308-1316.Jan C Becker, Wolfram Domschke, Thorsten Pohle. Current approaches to prevent NSAID-induced gastropathy - COX selectivity and beyond. Br J Clin Pharmacol, 2004 Dec; 58(6): 587-600.Jan C Becker, Wolfram Domschke, Thorsten Pohle. Current approaches to prevent NSAID-induced gastropathy - COX selectivity and beyond. Br J Clin Pharmacol, 2004 Dec; 58(6): 587-600.Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J. P., et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut, 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J. P., et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut, 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.Искаков Б. С., Кадирова Ф., Абдилова Д., Амзеева Т., и др. Гастродуоденальные риски антиагрегантной терапии при остром инфаркте миокарда. International Scientific and Practical Conference “WORLD SCIENCE”, 2015, № 4(4), Vol.2.Искаков Б. С., Кадирова Ф., Абдилова Д., Амзеева Т., и др. Гастродуоденальные риски антиагрегантной терапии при остром инфаркте миокарда. International Scientific and Practical Conference “WORLD SCIENCE”, 2015, № 4(4), Vol.2.Lin KJ, Hernandez-Diaz S, Garcia Rodriguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology, 2011;141:71-9. doi: 10.1053/j.gastro.2011.03.049.Lin KJ, Hernandez-Diaz S, Garcia Rodriguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology, 2011;141:71-9. doi: 10.1053/j.gastro.2011.03.049.Trenk D. Proton pump inhibitors for prevention of bleeding episodes in cardiac patients with dual antiplatelet therapy - between Scylla and Charybdis?. Int J Clin Pharmacol Ther, 2009;47:1-10. doi: 10.5414/CPP47001.Trenk D. Proton pump inhibitors for prevention of bleeding episodes in cardiac patients with dual antiplatelet therapy - between Scylla and Charybdis?. Int J Clin Pharmacol Ther, 2009;47:1-10. doi: 10.5414/CPP47001.Kim HK, Kim JI, Kim JK, Han JY, et al. Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci, 2007;52(8):1776-82.Kim HK, Kim JI, Kim JK, Han JY, et al. Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci, 2007;52(8):1776-82.Мороз Е. В., Каратеев А. Е. Pебамипид: эффективная медикаментозная профилактика НПВП-энтеропатии возможна. Современная ревматология, 2016; 10(4):97-105.Мороз Е. В., Каратеев А. Е. Pебамипид: эффективная медикаментозная профилактика НПВП-энтеропатии возможна. Современная ревматология, 2016; 10(4):97-105.Jhun J, Kwon J-E, Kim S-Y, et al. Rebamipide ameliorates atherosclerosis by controlling lipid metabolism and inflammation. PLoS ONE, 2017;12(2): e0171674. doi:10.1371/journal.pone.0171674.Jhun J, Kwon J-E, Kim S-Y, et al. Rebamipide ameliorates atherosclerosis by controlling lipid metabolism and inflammation. PLoS ONE, 2017;12(2): e0171674. doi:10.1371/journal.pone.0171674.Драпкина О. М., Корнеева О. Н. Поражения тонкой кишки при применении нестероидных противовоспалительных препаратов и антитромбоцитарной терапии. Подходы к профилактике и лечению. Терапевтический архив, 2016;88(12): 133-139.Драпкина О. М., Корнеева О. Н. Поражения тонкой кишки при применении нестероидных противовоспалительных препаратов и антитромбоцитарной терапии. Подходы к профилактике и лечению. Терапевтический архив, 2016;88(12): 133-139.Berger J. S., Stebbins A., Granger C. B. et al. Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation, 2008; 117: 192-199.Berger J. S., Stebbins A., Granger C. B. et al. Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation, 2008; 117: 192-199.James M Scheiman. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther, 2013; 15(Suppl 3): S 5.James M Scheiman. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther, 2013; 15(Suppl 3): S 5.Gawrońska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M., et al. CYP2C 19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol, 2012 Sep; 68(9): 1267-1274.Gawrońska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M., et al. CYP2C 19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol, 2012 Sep; 68(9): 1267-1274.Wedemeyer RS 1, Blume H. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update. Drug Saf, 2014 Apr;37(4):201-11. doi: 10.1007/s40264-014-0144-0.Wedemeyer RS 1, Blume H. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update. Drug Saf, 2014 Apr;37(4):201-11. doi: 10.1007/s40264-014-0144-0.Бордин Д. С. Что следует учитывать при выборе ингибитора протонной помпы больному ГЭРБ?. Медицинский альманах, 2010, № 1(10) март, с. 127-130.Бордин Д. С. Что следует учитывать при выборе ингибитора протонной помпы больному ГЭРБ?. Медицинский альманах, 2010, № 1(10) март, с. 127-130.Würtz M, Grove E. L. Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. Adv Exp Med Biol, 2017;906:325-350.Würtz M, Grove E. L. Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. Adv Exp Med Biol, 2017;906:325-350.Zou D., Goh KL. An East Asian Perspective on the Interaction between Proton Pump Inhibitors and Clopidogrel. J Gastroenterol Hepatol, 2016 Dec 26. doi: 10.1111/jgh.13712. (Epub ahead of print).Zou D., Goh KL. An East Asian Perspective on the Interaction between Proton Pump Inhibitors and Clopidogrel. J Gastroenterol Hepatol, 2016 Dec 26. doi: 10.1111/jgh.13712. (Epub ahead of print).Ших Е. В., Сычев Д. А. Безопасность пантопразола с позиций лекарственного взаимодействия. РЖГГК, 2012, т. 22, № 5, с. 4-12.Ших Е. В., Сычев Д. А. Безопасность пантопразола с позиций лекарственного взаимодействия. РЖГГК, 2012, т. 22, № 5, с. 4-12.Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther, 2011;89:65-74.Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther, 2011;89:65-74.Collet JP, Hulot JS, Abtan J, et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y 12 inhibition: results of the randomized DOSAPI study. Eur J Clin Pharmacol, 2014;70:1049-1057.Collet JP, Hulot JS, Abtan J, et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y 12 inhibition: results of the randomized DOSAPI study. Eur J Clin Pharmacol, 2014;70:1049-1057.Frelinger AL, 3rd, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lanso-prazole, esomeprazole, and omeprazole on the steady-state pharma-cokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol, 2012;59:1304-1311.Frelinger AL, 3rd, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lanso-prazole, esomeprazole, and omeprazole on the steady-state pharma-cokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol, 2012;59:1304-1311.Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol, 2008;48:475-484.Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol, 2008;48:475-484.Qi F., Zhu L, Li N., Ge T., et al. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. Int J Antimicrob Agents, 2017 Apr;49(4):403-409. doi: 10.1016/j.ijantimicag.2016.11.025. Epub 2017 Jan 31.Qi F., Zhu L, Li N., Ge T., et al. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. Int J Antimicrob Agents, 2017 Apr;49(4):403-409. doi: 10.1016/j.ijantimicag.2016.11.025. Epub 2017 Jan 31.Goodman SG, Clare R, Pieper KS, et al. Platelet Inhibition and Patient Outcomes Trial Investigators: association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation, 2012;125:978-986.Goodman SG, Clare R, Pieper KS, et al. Platelet Inhibition and Patient Outcomes Trial Investigators: association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation, 2012;125:978-986.Niu Q., Wang Z, Zhang Y, Wang J, et al. Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis. J Cardiovasc Pharmacol Ther, 2016 Aug 10. pii: 1074248416663647. (Epub ahead of print).Niu Q., Wang Z, Zhang Y, Wang J, et al. Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis. J Cardiovasc Pharmacol Ther, 2016 Aug 10. pii: 1074248416663647. (Epub ahead of print).Weisz G., Smilowitz N. R., Kirtane A. J., Rinaldi M. J., et al. Proton pump inhibitors, platelet reactivity, and cardiovascular outcomes after drug-eluting stents in clopidogrel-treated patients: The ADAPT-DES study. Circ. Cardiovasc. Interv, 2015;8: e001952.Weisz G., Smilowitz N. R., Kirtane A. J., Rinaldi M. J., et al. Proton pump inhibitors, platelet reactivity, and cardiovascular outcomes after drug-eluting stents in clopidogrel-treated patients: The ADAPT-DES study. Circ. Cardiovasc. Interv, 2015;8: e001952.Harvey A., Modak A., Dery U., Roy M., et al. Changes in CYP2C 19 enzyme activity evaluated by the ((13) C)-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity. J. Breath Res, 2016;10:017104. doi: 10.1088/1752-7155/10/1/017104.Harvey A., Modak A., Dery U., Roy M., et al. Changes in CYP2C 19 enzyme activity evaluated by the ((13) C)-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity. J. Breath Res, 2016;10:017104. doi: 10.1088/1752-7155/10/1/017104.Yucel E, Sancar M, Yucel A, Okuyan B. Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Expert Opin Drug Safe, 2016;15:223-36. doi: 10.1517/14740338.2016.1128413.Yucel E, Sancar M, Yucel A, Okuyan B. Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Expert Opin Drug Safe, 2016;15:223-36. doi: 10.1517/14740338.2016.1128413.Vaduganathan M., Cannon C. P., Cryer B. L., Liu Y., et al. Efficacy and safety of proton-pump inhibitors in high -risk cardiovascular subsets of the COGENT trial. Am. J. Med, 2016;129:1002-1005. doi: 10.1016/j.amjmed.2016.03.042.Vaduganathan M., Cannon C. P., Cryer B. L., Liu Y., et al. Efficacy and safety of proton-pump inhibitors in high -risk cardiovascular subsets of the COGENT trial. Am. J. Med, 2016;129:1002-1005. doi: 10.1016/j.amjmed.2016.03.042.O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet, 2009;374:989-997.O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet, 2009;374:989-997.Melloni C., Washam J. B., Jones W. S., Halim S. A., Hasselblad V., Mayer S. B., Heidenfelder B. L., Dolor R. J. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: Systematic review. Circ. Cardiovasc. Qual. Outcomes, 2015;8:47-55. doi: 10.1161/CIRCOUTCOMES.114.001177.Melloni C., Washam J. B., Jones W. S., Halim S. A., Hasselblad V., Mayer S. B., Heidenfelder B. L., Dolor R. J. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: Systematic review. Circ. Cardiovasc. Qual. Outcomes, 2015;8:47-55. doi: 10.1161/CIRCOUTCOMES.114.001177.Sherwood M. W., Melloni C., Jones W. S., Washam J. B. Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review. J Am Heart Assoc, 2015;4: e002245/.Sherwood M. W., Melloni C., Jones W. S., Washam J. B. Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review. J Am Heart Assoc, 2015;4: e002245/.Levine G. N., et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Levine G. N., et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Cardoso RN, Benjo AM, DiNicolantonio JJ, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart, 2015;2 doi: 10.1136/openhrt-2015-000248.Cardoso RN, Benjo AM, DiNicolantonio JJ, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart, 2015;2 doi: 10.1136/openhrt-2015-000248.Scarpignato C., Gatta L., Zullo A., Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med, 2016; 14: 179.Scarpignato C., Gatta L., Zullo A., Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med, 2016; 14: 179.Husted S, James S, Becker RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes, 2012;5:680-688.Husted S, James S, Becker RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes, 2012;5:680-688.Goodman S.G1., Clare R., Pieper K. S., Nicolau J., et al. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Circulation, 2012 Feb 28;125(8):978-86. doi: 10.1161/CIRCULATIONAHA.111.032912. Epub 2012 Jan 18.Goodman S.G1., Clare R., Pieper K. S., Nicolau J., et al. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Circulation, 2012 Feb 28;125(8):978-86. doi: 10.1161/CIRCULATIONAHA.111.032912. Epub 2012 Jan 18.Medication Guide Plavix® (PLAV-iks) (clopidogrel bisulfate) tablets.Medication Guide Plavix® (PLAV-iks) (clopidogrel bisulfate) tablets.Mistakes in the use of PPIs and how to avoid them. https://www.ueg.eu/education/latest-news/article/article/mistakes-in-alcoholic-liver-disease-and-how-to-avoid-them-copy-1/.Mistakes in the use of PPIs and how to avoid them. https://www.ueg.eu/education/latest-news/article/article/mistakes-in-alcoholic-liver-disease-and-how-to-avoid-them-copy-1/.Маев И. В., Самсонов А. А., Годило-Годлевский В.А., Андреев Д. Н., Дичева Д. Т. Лекарственное взаимодействие ингибиторов протонной помпы и клопидогреля при их совместном приеме. Клиническая медицина, 2013, № 5, С. 15-21.Маев И. В., Самсонов А. А., Годило-Годлевский В.А., Андреев Д. Н., Дичева Д. Т. Лекарственное взаимодействие ингибиторов протонной помпы и клопидогреля при их совместном приеме. Клиническая медицина, 2013, № 5, С. 15-21.Guérin A., Mody R., Carter V., Ayas C. Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication. PLoS One, 2016 Jan 4;11(1): e0145504. doi: 10.1371/journal.pone.0145504. eCollection 2016.Guérin A., Mody R., Carter V., Ayas C. Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication. PLoS One, 2016 Jan 4;11(1): e0145504. doi: 10.1371/journal.pone.0145504. eCollection 2016.Moceri P, Doyen D, Cerboni P, Ferrari E. Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. Thromb Res, 2011;128:458-462.Moceri P, Doyen D, Cerboni P, Ferrari E. Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. Thromb Res, 2011;128:458-462.Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J, 2013;34:1708-1713.Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J, 2013;34:1708-1713.

The authors declare that there are no conflicts of interest present.